Abstract
Background Aneuploidy, the state of a cell containing extra or missing chromosomes, frequently arises during human meiosis and is the primary cause of early miscarriage and maternal age-related in vitro fertilization (IVF) failure. IVF patients exhibit significant variability in aneuploidy rates, although the exact genetic causes of the variability in aneuploid egg production remain unclear. Preimplantation genetic testing for aneuploidy (PGT-A) using ultra-low coverage whole-genome sequencing (ulc-WGS) is a standard test for identifying and selecting IVF-derived embryos with a normal chromosome complement. The wealth of embryo aneuploidy data and ulc-WGS data from PGT-A has potential for discovering variants in paternal genomes that are associated with aneuploidy risk in their embryos.
Methods Using ulc-WGS data from ∼10,000 PGT-A biopsies, we imputed genotype likelihoods of genetic variants in parental genomes. We then used the imputed variants and aneuploidy calls from the embryos to perform a genome-wide association study of aneuploidy incidence. Finally, we carried out functional evaluation of the identified candidate gene in a mouse oocyte system.
Results We identified one locus on chromosome 3 that is significantly associated with maternal meiotic aneuploidy risk. One candidate gene, CCDC66, encompassed by this locus, is involved in chromosome segregation during meiosis. Using mouse oocytes, we showed that CCDC66 regulates meiotic progression and chromosome segregation fidelity, especially in older mice.
Conclusions Our work extended the research utility of PGT-A ulc-WGS data by allowing robust association testing and improved the understanding of the genetic contribution to maternal meiotic aneuploidy risk. Importantly, we introduce a generalizable method that can be leveraged for similar association studies using ulc-WGS data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is partly supported by the NIH/NICHD grant R01-HD091331 to KS and JX. R.C.M. is supported by grant R35GM133747 from the NIH/NIGMS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Rutgers University determined that this work does not qualify as federally regulated human subjects research (Pro2023001490).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
List of abbreviations
- IVF
- in vitro fertilization
- PGT-A
- preimplantation genetic testing for aneuploidy
- ulc-WGS
- ultra-low-coverage whole-genome sequencing
- GWAS
- genome-wide association studies
- PC
- principal component
- GL
- genotype likelihood
- MAF
- minor allele frequency
- GLM
- generalized linear regression model
- SNP
- single nucleotide polymorphism
- FDR
- false discovery rate
- MEM
- minimum essential medium
- CZB
- Chatot, Ziomek, and Bavister
- PFA
- paraformaldehyde
- PBS
- phosphate-buffered saline
- DAPI
- 4, 6-Diamidino-2-Phenylindole, Dihydrochloride
- eQTLs
- expression quantitative trait loci
- PBE
- extruded polar bodies
- NIPT
- non-invasive prenatal testing
- cfDNA
- cell-free DNA
